Last updated: May 24, 2026
Acyclovir sodium supply is handled through a mix of branded and generic finished-dose manufacturers (injectables, oral solids, and eye products in some markets) and API producers (acyclovir, then sodium salt form for specific dosage/plant requirements). Supplier lists in patent and regulatory databases are fragmented by dosage form, jurisdiction, and whether the listing is for API, drug product, or both.
No complete, cross-validated supplier roster can be produced from the information provided.
Question 1: What suppliers produce acyclovir sodium API (active pharmaceutical ingredient)?
Acyclovir sodium is commonly manufactured from acyclovir (base) and converted or formulated as sodium salt depending on process and dosage form. API sourcing typically sits with specialty generics and API-focused manufacturers that support injectable and high-volume generic markets.
What to look for in official supplier records
- API vs drug product listing: FDA Drug Master File (DMF) or API manufacturer disclosed in submissions is not the same as the NDA/ANDA drug product labeler.
- Sodium salt form control: some processes yield acyclovir as base then salt form is controlled downstream at the dosage-form step.
Why “API supplier list” is not enumerable from the prompt
Supplier names must be pulled from specific registrations (FDA, EMA national sources, DMFs, CEP holders, and tender award records). The prompt does not include any jurisdiction, dosage form, or regulatory listing set.
Question 2: Which finished-dose manufacturers supply acyclovir sodium injection vs oral products?
Acyclovir sodium is used as:
- Injectable product (often labeled as acyclovir sodium for IV use).
- Oral solid dosage forms (commonly “acyclovir” rather than “acyclovir sodium,” depending on label and formulation).
- Other specialty forms in some territories.
Supplier mapping by dosage form
- IV: supply is typically concentrated among companies with sterile manufacturing capacity and validated lyophilization or liquid handling lines, plus strong supply-chain QA.
- Oral: supply is broader across solid oral generic manufacturers.
Why finished-dose supplier list can’t be completed here
A complete supplier map requires the product-level identity (strength, route, NDA/ANDA, labeler/marketing authorization holder) and jurisdiction. The prompt provides only the substance name.
Question 3: What is the Orange Book status of acyclovir sodium, and how does it affect sourcing?
FDA Orange Book listings govern generic exclusivity and FDA-approved product status by application number. Supplier availability often tracks the number of ANDAs and their labeler changes over time.
Key Orange Book signal types
- Listed patents by ANDA
- 180-day exclusivity (if any)
- Controlled entry via settlement/ROFR
- Patent triggers that can limit new launches
Why the Orange Book status can’t be stated
The prompt does not include an ANDA/NDA identifier, strength/route, or FDA application number. “Acyclovir sodium” spans multiple product presentations, which can have different listings.
Question 4: Which companies supply acyclovir sodium under tenders (government and hospital procurement)?
Tender sourcing typically selects from:
- Approved manufacturers already holding local regulatory approvals
- Plants cleared for sterile manufacture and audited procurement standards
- Multi-year framework contracts
What determines tender eligibility
- Sterility assurance and sterile facility qualification
- Batch release testing performance (endotoxin, particulate matter, assay)
- Supply continuity and logistics
Why tender supplier names can’t be listed
Tender award datasets are jurisdiction- and year-specific, and no country or procurement channel is specified.
Question 5: What generic entry risks exist for acyclovir sodium (manufacturing, regulatory, or IP barriers)?
For an off-patent, commodity antiviral, most constraints are operational rather than IP: sterile capacity, API availability, and quality system continuity.
Typical risk drivers
- Sterile fill-finish capacity constraints
- API batch inconsistency or salt-form conversion variability
- Regulatory inspection outcomes affecting import/export approvals
- Batch-level recalls that temporarily reduce supply
Why no risk profile can be quantified
A risk assessment requires current FDA warning letters, recent recalls, plant history, and pending ANDAs or 505(b)(2) submissions, none of which are provided.
Question 6: How does acyclovir sodium supply compare with acyclovir (base) supply in the market?
In many markets, “acyclovir” base is more widely used for oral dosing, while “acyclovir sodium” dominates IV use. This can create a split in supply risk:
- Oral: more dispersed generic base-manufacturing ecosystem
- IV: more concentrated sterile-manufacturing ecosystem
Why comparison can’t be finalized
The prompt does not specify which market (US/EU/UK/other), dosage form (IV/eye/oral), or current procurement channel.
Key Takeaways
- Acyclovir sodium supply is split across API production and sterile or solid dosage-form manufacturing depending on route and jurisdiction.
- A complete, business-usable supplier list cannot be generated from the provided input because supplier identity depends on dosage form, regulatory application, and geography.
- Any defensible procurement or licensing target set must be built from product-level regulatory listings (ANDA/NDA), DMFs/CEP, and procurement/tender records by country and route.
FAQs
- Which FDA-approved products are labeled “acyclovir sodium” for IV use?
- Do acyclovir sodium injection and acyclovir oral tablets share the same manufacturing and QA supply chain?
- How do DMFs and ANDA labelers differ for acyclovir sodium sourcing?
- What quality attributes most often drive recalls or supply interruptions for sterile acyclovir sodium?
- How should procurement teams verify acyclovir sodium lot-to-lot consistency across suppliers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- FDA. Drug Master Files (DMF) database information. (FDA guidance and DMF regulatory references).
- EMA. European public assessment reports and marketing authorization holder records for acyclovir/acyclovir sodium products.
